UPEC

LinKinVax Just Completed a New Round of Financing, Initiated in 2022, for a Total of €7,3 M 

Retrieved on: 
Monday, January 9, 2023
Oncology, Health, Infectious Diseases, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Ooredoo, PIA, HPV, B cell, University, Coronaviridae, Biomedical Research, Chlamydia, HIV, Public health, Vaccine Research Center, Government, Vaccine, VRI, Infection, Immune system, UPEC, IQT, Cancer, IMRB, University of Paris-Est Marne-la-Vallée

LinKinVax’s innovative technology directly targets dendritic cells (“DC”), which play a crucial role in the immune system, stimulating and regulating immune responses.

Key Points: 
  • LinKinVax’s innovative technology directly targets dendritic cells (“DC”), which play a crucial role in the immune system, stimulating and regulating immune responses.
  • It is predicated on work by the Vaccine Research Institute/Inserm (VRI) in which Inserm, University of Paris Est Créteil (UPEC), and the Mondor Institute of Biomedical Research (IMRB) participate.
  • Englehart, Director, IQT International Ltd UK: “We are impressed by LinKinVax’s team and its vision for developing world-class vaccine technology.
  • This new financing, completed in December 2022, includes a seed funding from private shareholders, beginning of 2022.

Intel Names Hardware Security Award Winners

Retrieved on: 
Wednesday, August 10, 2022
Technology, Semiconductor, Security, Software, Networks, Hardware, University, Data Management, Education, Artificial Intelligence, IDM, Transfer, EPT, Intel, Curriculum, Industry, Faculty, Technology, Socs, SOC, Emerging, Confidentiality, Hardware, Research, Environment, X86 virtualization, Register transfer language, Central processing unit, Program, Award, Artificial intelligence, PML, UPEC, RTL, Solution, Conference, Hypervisor, USENIX, Risk management, Pharmaceutical industry

Whats New: Today, Intel announced the winners of its second annual Intel Hardware Security Academic Award program, aimed at fostering innovative research into solutions, tools and methodologies to address fundamental security challenges and enhance the industrys ability to deliver more secure and trustworthy foundational technologies.

Key Points: 
  • Whats New: Today, Intel announced the winners of its second annual Intel Hardware Security Academic Award program, aimed at fostering innovative research into solutions, tools and methodologies to address fundamental security challenges and enhance the industrys ability to deliver more secure and trustworthy foundational technologies.
  • Intel has a long history of working closely with academic researchers to tackle big challenges through programs like Intel Labs academic and faculty research grants, the Intel Bug Bounty program, and now through the hardware security award.
  • About the Award Program: The Hardware Security Academic Award program is part of Intels commitment to collaborate with and foster advancements in the security research community.
  • This research demonstrates how modern hardware features (Intel Virtualization Technology, extended page tables [EPT], Intel Processor Trace, and page-modification logging [PML]) can be used to build effective and innovative security validation tools.

Coave Therapeutics Announces Formation of Scientific Advisory Board to Drive its Pipeline Strategy for Next-generation Gene Therapies Targeting CNS Diseases

Retrieved on: 
Thursday, June 30, 2022
Central nervous system, Knowledge, Patient, Research, Harvard Medical School, Re Recher's Will Trusts, CNS, Degenerative disease, SAB, UPEC, University of Paris, Coronavirus Scientific Advisory Board (Turkey), Neurology, Doctor of Philosophy, UAB Hospital, Eye, Neurosurgery, Board, MD, Therapy, Neurodegeneration, Medical device, Vaccine, Management, Pharmaceutical industry, Hospital, Medicine, Neuroscience, Idinvest Partners, Genetics

PARIS, June 30, 2022 /PRNewswire/ -- Coave Therapeutics ('Coave'), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, announces the formation of its Scientific Advisory Board (SAB) comprising international scientific and clinical experts in neurology and gene therapy.

Key Points: 
  • PARIS, June 30, 2022 /PRNewswire/ -- Coave Therapeutics ('Coave'), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, announces the formation of its Scientific Advisory Board (SAB) comprising international scientific and clinical experts in neurology and gene therapy.
  • The newly formed SAB will provide Coave with expert guidance on its current and future research and development strategy, which includes a pipeline of next-generation gene therapy candidates targeting neurodegenerative diseases.
  • Coave Therapeutics is a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases.
  • Coave Therapeutics' next-generation AAV-Ligand Conjugate ('ALIGATER') platform enables targeted delivery and enhanced gene transduction to improve the effectiveness of advanced gene therapies for rare diseases.

Coave Therapeutics Announces Formation of Scientific Advisory Board to Drive its Pipeline Strategy for Next-generation Gene Therapies Targeting CNS Diseases

Retrieved on: 
Thursday, June 30, 2022
Central nervous system, Knowledge, Patient, Research, Harvard Medical School, Re Recher's Will Trusts, CNS, Degenerative disease, SAB, UPEC, University of Paris, Coronavirus Scientific Advisory Board (Turkey), Neurology, Doctor of Philosophy, UAB Hospital, Eye, Neurosurgery, Board, MD, Therapy, Neurodegeneration, Medical device, Vaccine, Management, Pharmaceutical industry, Hospital, Medicine, Neuroscience, Idinvest Partners, Genetics

PARIS, June 30, 2022 /PRNewswire/ -- Coave Therapeutics ('Coave'), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, announces the formation of its Scientific Advisory Board (SAB) comprising international scientific and clinical experts in neurology and gene therapy.

Key Points: 
  • PARIS, June 30, 2022 /PRNewswire/ -- Coave Therapeutics ('Coave'), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, announces the formation of its Scientific Advisory Board (SAB) comprising international scientific and clinical experts in neurology and gene therapy.
  • The newly formed SAB will provide Coave with expert guidance on its current and future research and development strategy, which includes a pipeline of next-generation gene therapy candidates targeting neurodegenerative diseases.
  • Coave Therapeutics is a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases.
  • Coave Therapeutics' next-generation AAV-Ligand Conjugate ('ALIGATER') platform enables targeted delivery and enhanced gene transduction to improve the effectiveness of advanced gene therapies for rare diseases.

LINKINVAX Raises €4.350 Million in Funding

Retrieved on: 
Thursday, February 10, 2022
Research, Infectious Diseases, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, VRI, Industry, B cell, Medicine, IMRB, Doctor of Philosophy, Coronaviridae, Research, Immune system, Biomedical Research, Cancer, HIV, CD40, PIA, Infection, Technology, Vaccine Research Center, University, Antigen, HPV, CEO, University of Paris-Est Marne-la-Vallée, Vaccine, SOITEC, UPEC, Public health, MD, LinKinVax technology, LinKinVax, LINKINVAX TECHNOLOGY, LINKINVAX

LinKinVax, a clinical-stage biotechnology company is announcing completion of a 4.350 million seed capital funding round.

Key Points: 
  • LinKinVax, a clinical-stage biotechnology company is announcing completion of a 4.350 million seed capital funding round.
  • LinKinVax has already risen to prominence in the French sector, with Bpifrance granting it 31 million under a Covid-related PIA PSCP program and Government Plan Relance , in May 2021.
  • LinKinVaxs innovative technology directly targets dendritic cells (DC), which play a crucial role in the immune system, stimulating and regulating immune responses.
  • LinKinVax is developing an innovative protein-based vaccine platform that can accelerate availability of vaccines by leveraging the research conducted at the Vaccine Research Institute (VRI).

LinKinVax and Inserm Transfert Enter Into an Exclusive Worldwide Licensing Agreement Covering Use of an Innovative Vaccine Platform

Retrieved on: 
Thursday, February 3, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Other Health, CEO, UPEC, Entrepreneurship, Immune system, Cell, IMRB, University, MD, VRI, University of Paris-Est Marne-la-Vallée, SOITEC, Technology, Research, Vaccine Research Center, Biomedical Research, HIV, Medicine, Public service, Antigen, Public health, Health, Medical research, Vaccine, Knowledge, Doctor of Philosophy, Severe acute respiratory syndrome coronavirus 2, Industry, CD40, Technology transfer, B cell, National Institute, Chlamydia, Pharmaceutical industry, Inserm, LinKinVax technology, LinKinVax, Inserm Transfert, LINKINVAX TECHNOLOGY, LINKINVAX, INSERM TRANSFERT

LinKinVax, a clinical-stage biotech company, is announcing the signing of an exclusive worldwide licensing agreement with Inserm Transfert to develop a vaccine strategy with an innovative mechanism of action.

Key Points: 
  • LinKinVax, a clinical-stage biotech company, is announcing the signing of an exclusive worldwide licensing agreement with Inserm Transfert to develop a vaccine strategy with an innovative mechanism of action.
  • LinKinVax is developing a vaccine platform that directly targets dendritic cells.
  • This research has accelerated adaptation of this vaccine platform to several infectious agents, including SARS-CoV-2 with a universal approach to cover multiple variants.
  • LinKinVax is developing an innovative protein-based vaccine platform that can accelerate availability of vaccines by leveraging the research conducted at the Vaccine Research Institute (VRI).